Lilly's Solpura Advisory Committee Could Hinge On Manufacturing Issues
This article was originally published in The Pink Sheet Daily
Executive Summary
Alnara, a Lilly subsidiary, says that its exocrine pancreatic insufficiency treatment is supported by two adequate and well-controlled trials, but FDA says that the product has changed so much that only one of them is relevant - and that one doesn't show strong enough efficacy.
You may also be interested in...
In A Manufacturing Dispute With FDA, Can A Sponsor Get Help From An Advisory Committee?
As biosimilars loom on the horizon and a number of innovator biologics face the prospect of having to switch production facilities to accommodate growing demand, the advisory committee review of Eli Lilly & Co.'s application for Sollpura illustrates the challenges that a sponsor may face if it disagrees with FDA about a manufacturing issue.
In A Manufacturing Dispute With FDA, Can A Sponsor Get Help From An Advisory Committee?
As biosimilars loom on the horizon and a number of innovator biologics face the prospect of having to switch production facilities to accommodate growing demand, the advisory committee review of Eli Lilly & Co.'s application for Sollpura illustrates the challenges that a sponsor may face if it disagrees with FDA about a manufacturing issue.
Sollpura's Future After No Vote From Panel Might Include More Trials, Adult Indication
FDA's Gastrointestinal Drugs Advisory Committee says in lopsided votes that Lilly's exocrine pancreatic insufficiency drug candidate Sollpura (liprotamase) lacks proof of efficacy.